10-Q: Nuwellis Reports First Quarter 2025 Results, Cites Ongoing Efforts to Secure Additional Funding

Nuwellis, Inc. reports its financial results for the first quarter of 2025, highlighting a slight increase in net sales but continued losses and efforts to secure additional capital.

Summary

• Nuwellis, Inc., a medical device company focused on fluid overload solutions, reported its financial results for the quarter ended March 31, 2025.
• Net sales increased slightly to $1.904 million compared to $1.857 million in the same period last year, driven by a 4% increase in circuit sales and an increase in console sales.
• The company experienced a net loss of $3.014 million, compared to a net loss of $4.330 million in the first quarter of 2024.
• The company's cost of goods sold increased to $837,000 from $666,000 due to unfavorable manufacturing variances and lower fixed overhead absorption.
• Selling, general, and administrative expenses decreased to $3.577 million from $4.606 million due to decreased headcount and compensation-related expenses.
• Research and development expenses decreased to $550,000 from $1.334 million due to decreased headcount and reduced R&D project spending.
• As of March 31, 2025, Nuwellis had cash and cash equivalents of $2.557 million, down from $5.095 million at the end of 2024.
• The company believes its existing capital resources will be sufficient to support its operating plan through May 31, 2025.
• Nuwellis is actively seeking additional capital through debt, equity, or a combination thereof to support its growth and strategic initiatives.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern through at least twelve months from the filing date.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the ongoing losses, decreasing cash reserves, and the auditor's concerns about the company's ability to continue as a going concern. While there was a slight increase in net sales and a decrease in net loss, the overall financial situation remains precarious.

Positives

• Net sales increased by 2.5% compared to the same period last year.
• Net loss decreased from $4.330 million to $3.014 million year-over-year.
• The company reduced its monthly cash burn rate by approximately 40% in 2024.
• A new agreement with KDI Precision Manufacturing is expected to expand manufacturing capabilities and streamline operations.

Negatives

• The company experienced a net loss of $3.014 million for the quarter.
• Cash and cash equivalents decreased significantly from the end of 2024.
• Auditors have raised substantial doubt about the company's ability to continue as a going concern.
• The company has identified two material weaknesses in controls over financial reporting.

Risks

• The company's ability to continue as a going concern is uncertain without additional funding.
• The company may not be successful in raising additional capital.
• The company is dependent on sole source suppliers for raw materials.
• Failure to comply with federal and state laws regarding off-label use of products could result in penalties.
• Changes to U.S. tariff and import/export regulations may negatively impact suppliers and service providers.
• Changes in U.S. federal government funding for the FDA could hinder its ability to approve new products.
• The company has identified two material weaknesses in controls over financial reporting.

Future Outlook

The company expects to incur additional losses in the near-term as it grows the Aquadex Business and is seeking to raise additional capital to support its growth or other strategic initiatives through debt, equity, or a combination thereof.

Management Comments

• The company is focused on commercializing the Aquadex SmartFlow system for ultrafiltration therapy.
• The company is dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation.

Industry Context

Nuwellis operates in the medical device industry, specifically focusing on fluid overload solutions. The company's performance is influenced by factors such as hospital spending, adoption of new medical technologies, and regulatory approvals. The agreement with KDI Precision Manufacturing reflects a trend in the industry towards outsourcing manufacturing to improve efficiency and reduce costs.

Comparison to Industry Standards

• It's difficult to directly compare Nuwellis to industry giants like Baxter International (from whom they acquired the Aquadex business) or Fresenius Medical Care, as those companies have diversified product portfolios.
• Smaller, more focused medical device companies like Nuwellis often face challenges in scaling their operations and securing funding compared to larger, more established players.
• The company's reliance on equity financing is common for early-stage medical device companies, but it can be dilutive to existing shareholders.
• The identified material weaknesses in internal controls are a concern, as robust internal controls are essential for maintaining investor confidence and regulatory compliance, similar to the standards expected of companies like Medtronic or Boston Scientific.

Stakeholder Impact

• Shareholders face the risk of dilution if the company raises additional capital through equity offerings.
• Employees may be affected by cost-cutting measures or restructuring efforts.
• Customers (hospitals and clinics) may benefit from the expanded manufacturing capabilities and improved product availability resulting from the agreement with KDI Precision Manufacturing.
• Suppliers may be impacted by changes in the company's sourcing strategies.
• Creditors face increased risk due to the company's uncertain financial position.

Next Steps

• The company will seek to raise additional capital to support its growth or other strategic initiatives.
• The company will continue to focus on expanding the adoption and market acceptance of the Aquadex System.
• The company will work with KDI Precision Manufacturing to expand manufacturing capabilities and streamline operations.
• The company expects to perform additional analyses, reconciliations, and remediations to address the identified material weaknesses in controls over financial reporting.

Key Dates

Keywords

Nuwellis, Aquadex, Financial Results, Fluid Overload, Medical Device, Ultrafiltration, Net Sales, Net Loss, Capital Resources, Going Concern